An interventional study of Control group (ambrisentan plus tadalafil or macitentan plus tadalafil) and Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil) in Congenital Heart Disease, Pulmonary Hypertension, sponsored by China National Center for Cardiovascular Diseases. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases — 5 open to participants now, 6 under way, none of them phase 3. Heart Defects, Congenital · China National Center for Cardiovascular Diseases.
Among the 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases, this one is one of 6 that started in 2022, is one of 2 with no phase, and was the 10th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →5 of the 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
China National Center for Cardiovascular Diseases · Sites in China
Ages up to 14
China National Center for Cardiovascular Diseases · Sites in China
Ages up to 14
China National Center for Cardiovascular Diseases · Sites in China
Ages up to 14
China National Center for Cardiovascular Diseases · Sites in China
Ages up to 14
By country, each count listing its studies:
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 6 started in 2022.
This study's enrollment of 30 is below the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 69 across the 2 interventional studies, 210 across the 8 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to observe the efficacy of early application of triple targeted drug therapy, including trilostane, in patients with congenital heart disease who are in the "gray zone" of preoperative evaluation, have surgical repair indications after evaluation, and have undergone defect repair.
This study is a prospective randomized controlled study. Including congenital heart disease combined with pulmonary hypertension, the hemodynamics in the right heart catheter before surgery conform to the "gray zone standard" (PVRi: 6-8 Wood * m2) in the 2018 Cologne Consensus.PVR/SVR 0.3-05), acute vascular reaction test met the positive standard (PVRi: \< 6 Wood*m 2, PVR/SVR \< 0.3), and CHD patients (including VSD, PDA, ASD) who underwent surgical repair, patients were randomly assigned to different treatment groups, The specific grouping is as follows: 1) 15 patients in the standard dual therapy group received dual therapy for 12 months, consisting of a phosphodiesterase type 5 inhibitor (tadalafil 20 mg qd or sildenafil 20\~25 mg tid) combined with a phosphodiesterase 5 receptor antagonist (amlodipine 5 mg qd or macitentan 10 mg qd). 2) 15 patients in the early triple therapy group received the combination of a phosphodiesterase type 5 inhibitor (tadalafil 20 mg qd or sildenafil 20\~25 mg tid), a phosphodiesterase-5 receptor antagonist (amlodipine 5 mg qd or maropitant 10 mg qd), and treprostinil. The dosage of pralatrexate needs to be titrated gradually, starting from 1.25 ng/min/kg, and titrated gradually to the patient's maximum tolerated dose (guideline dose of 15-20 ng/min/kg), and the duration of triple targeted drug therapy is at least 6 months. After 6 months, it can be adjusted to the standard dual therapy group to 12 months. Observation indexes The main observation indices are as follows:(1) Pulmonary vascular resistance measured by right heart catheterization one year after surgical repair and closure of defects. Secondary observation indicators: (1) Right atrial pressure, pulmonary artery pressure, PVR/SVR, cardiac index, mixed blood oxygen saturation, and systemic arterial blood oxygen saturation measured in right heart catheterization 12 months after surgery. (2) NT-proBNP level (3) 6-minute walk distance (4) WHO functional class (5) SF-36 self-assessment quality of life score (6) rehospitalization due to worsening heart failure, atrial septal defect shunt, lung transplant or heart-lung transplant, and other adverse events; (7) Drug-related adverse reaction events, including but not limited to hypotension, headache, muscle pain, injection site pain, injection site infection, bleeding, etc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ambrisentan 10mg qd or Macitentan 10mg qd combined with Tadalafil 20-40mg qd
Drug: Control group (ambrisentan plus tadalafil or macitentan plus tadalafil)
Ambrisentan 10mg qd or Macitentan 10mg qd combined with Tadalafil 20-40mg qd and Treprostinil
Drug: Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil)
The control group received dual drug therapy: endothelin receptor antagonists (Ambrisentan 10mg qd, or Macitentan 10mg qd) combined with phosphodiesterase type 5 inhibitors (Tadalafil 20-40mg qd).
The treatment group received early triple therapy: endothelin receptor antagonist (Ambrisentan 10 mg qd or Macitentan 10 mg qd), a phosphodiesterase type 5 inhibitor ( Tadalafil 20-40 mg qd), and treprostinil. The Treprostinil dose was titrated gradually, starting at 1.25 ng/min/kg and escalated to the patient's maximum tolerated dose (target dose range: 15-20 ng/min/kg).
Pulmonary vascular resistance
Pulmonary vascular resistance measured by right heart catheterization
Time frame: 12 months after surgical closure of the defect
Right atrial pressure
The right atrial pressure was measured by the right heart catheterization
Time frame: 12 months after surgery
Pulmonary artery pressure
Pulmonary artery pressure measured by the right heart catheterization
Time frame: 12 months after surgical closure of the defect
Ratio of pulmonary vascular resistance to systemic vascular resistance
Pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) were calculated from hemodynamic parameters obtained during right heart catheterization (RHC). PVR was calculated as (mean pulmonary artery pressure - pulmonary artery wedge pressure) divided by cardiac output. SVR was calculated as 80 × (mean arterial pressure - right atrial pressure) divided by cardiac output.
Time frame: 12 months after surgical closure of the defect
Cardiac index
Cardiac index was calculated as cardiac output divided by body surface area. Cardiac output was measured during right heart catheterization.
Time frame: 12 months after surgical closure of the defect
Mixed venous oxygen saturation
Mixed venous oxygen saturation was sampled and measured from the main pulmonary artery during right heart catheterization.
Time frame: 12 months after surgical closure of the defect
Systemic arterial blood oxygen saturation
Systemic arterial blood oxygen saturation was determined from arterial blood samples obtained during right heart catheterization.
Time frame: 12 months after surgical closure of the defect
NT-proBNP
Laboratory examination
Time frame: 12 months after surgery
6 minutes walking distance
On a flat, hard surface, the maximum distance walked by the subject at their own pace in 6 minutes
Time frame: 12 months after surgery
WHO heart function grading
The standard set by the World Health Organization to assess the functional status of patients with heart disease: Grade I: No limitation in physical activity, no symptoms in daily activities Grade II: Mild limitation of activity, nothing happens when resting, but there will be shortness of breath and fatigue during daily activities. Level III: Activities are significantly limited, there is no problem when resting, but symptoms will be triggered by slight activities (below daily intensity). Grade IV: The most severe, symptoms are present at rest and worsen with any activity, and there may be signs of right heart failure.
Time frame: 12 months after surgery
The MOS 36-Item Short Form Health Survey (SF-36)
The MOS 36-Item Short Form Health Survey (SF-36) was used to assess health-related quality of life. Each of its eight domains, as well as the physical component summary (PCS) and mental component summary (MCS), ranges from 0 to 100, with higher scores indicating better health status.
Time frame: 12 months after surgery
All kinds of adverse events
Rehospitalization due to worsening heart failure, ventricular septal defect repair, lung transplantation or heart-lung transplantation, and other adverse events
Time frame: 12 months after surgery
Adverse drug reaction events
Not limited to low blood pressure, headache, muscle soreness, injection site pain,Injection site infection, bleeding, etc.
Time frame: 12 months after surgery
Plan to share: No — Ethically, raw data contains sensitive personal information, and initial informed consent is often not authorized for external sharing, which may infringe on privacy and violate the trust of participants. From a legal perspective, strict compliance with relevant data protection regulations is required, and there are compliance risks and contractual constraints when transferring data across borders or to third parties. In practice, the establishment of a secure sharing platform is costly, and the degree of data standardization is inconsistent, which may lead to misunderstandings or misuses and affect the credibility of research.
Ran from Aug 2022 to primary completion in Jul 2025, 35 months.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 35 months is close to that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →